Please assess the completion status of the following clinical trial:

Trial Title: MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a cancer diagnosis, receiving chemotherapy, radiation therapy or the combination~* Patients with a current diagnosis of oral mucositis~* Patients with pain and oral dysfunction associated with oral mucositis despite conventional therapy~* Voluntary written consent~* Patient must agree to use of contraception or abstinence from sex during the treatment period and for 30 days after patient's last dose~Exclusion Criteria:~* Patients with known allergy to MB~* Patients taking medications with known significant drug interactions~* Pregnant or lactating patients~* Patients who are cognitively impaired and unable to consent for the study~* Patients with risk of broncho-aspiration based on documented swallowing test by a speech pathologist (if available)~* Patients with known history of G6PD deficiency~* Patients undergoing any other experimental intervention for oral mucositis~* Patients who have no pain or impairment in oral function, patients who are not symptomatic~* Patients with head and neck cancer~* Patients on serotonergic drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (lower dose methylene blue, standard of care) (Type: EXPERIMENTAL): Patients receive lower dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
- Group 2 (medium dose methylene blue, standard of care) (Type: EXPERIMENTAL): Patients receive medium dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
- Group 3 (higher dose methylene blue, standard of care) (Type: EXPERIMENTAL): Patients receive higher dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
- Group 4 (standard of care) (Type: ACTIVE_COMPARATOR): Patients receive standard of care therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).